HUP0201224A2 - Glioblasztóma kezelésére alkalmas rákellenes szert tartalmazó biodegradálható mikrogömbök alkalmazása gyógyszer termék előállítására - Google Patents

Glioblasztóma kezelésére alkalmas rákellenes szert tartalmazó biodegradálható mikrogömbök alkalmazása gyógyszer termék előállítására

Info

Publication number
HUP0201224A2
HUP0201224A2 HU0201224A HUP0201224A HUP0201224A2 HU P0201224 A2 HUP0201224 A2 HU P0201224A2 HU 0201224 A HU0201224 A HU 0201224A HU P0201224 A HUP0201224 A HU P0201224A HU P0201224 A2 HUP0201224 A2 HU P0201224A2
Authority
HU
Hungary
Prior art keywords
biodegradable microspheres
microspheres
anticancer agent
gliobastoma
treating
Prior art date
Application number
HU0201224A
Other languages
English (en)
Inventor
Jean-Pierre Benoit
Nathalie Faisant
Philippe Menei
Original Assignee
Laboratoires Des Produits Ethiques Ethypharm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoires Des Produits Ethiques Ethypharm filed Critical Laboratoires Des Produits Ethiques Ethypharm
Publication of HUP0201224A2 publication Critical patent/HUP0201224A2/hu
Publication of HUP0201224A3 publication Critical patent/HUP0201224A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

A találmány tárgya rádioaktív sugárzással szemben szenzibilizálórákellenes szert tartalmazó biodegradálódó mikrogömbök alkalmazásagyógyszertermék előállítására. A találmány szerinti biodegradálódómikrogömbök alkalmazásával a betegek túlélési ideje legalább 90 hét,ezen időtartam alatt a parenchymatikus területen terápiásan hatásoskoncentráció áll fenn. A mikrogömbök előnyösen 5-fluoruracilttartalmaznak 5-(d,l-tejsav-ko-glikolsav) polimerrel bevonva. Amikrogömböket a tumor kimetszése után az operáció helyének falábainjektálják intratisszuláris injekcióval. A tumortömeget célzórádioterápiát körülbelül 6 hétig végzik 60 Gy dózisban. A találmánykiterjed a biodegradálódó mikrogömbök emulziós-extrakciós eljárássaltörténő előállítására és az ilyen eljárással előállítottbiodegradálódó mikrogömböket tartalmazó szuszpenzióra is. Ó
HU0201224A 1999-05-17 2000-05-17 Use of biodegradable microspheres that release an anticancer agent for treating gliobastoma HUP0201224A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9906207A FR2793684B1 (fr) 1999-05-17 1999-05-17 Utilisation de microspheres biodegradables liberant un agent anticancereux pour le traitement du glioblastome, procede de preparation de ces microspheres et suspension les contenant

Publications (2)

Publication Number Publication Date
HUP0201224A2 true HUP0201224A2 (hu) 2002-11-28
HUP0201224A3 HUP0201224A3 (en) 2004-05-28

Family

ID=9545636

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0201224A HUP0201224A3 (en) 1999-05-17 2000-05-17 Use of biodegradable microspheres that release an anticancer agent for treating gliobastoma

Country Status (30)

Country Link
US (2) US6803052B2 (hu)
EP (2) EP1228755A1 (hu)
JP (1) JP5230045B2 (hu)
KR (1) KR100649948B1 (hu)
CN (1) CN1210020C (hu)
AR (1) AR024008A1 (hu)
AT (1) ATE228353T1 (hu)
AU (1) AU775320B2 (hu)
BG (1) BG64936B1 (hu)
BR (1) BR0010648A (hu)
CA (1) CA2388656C (hu)
CZ (1) CZ20014137A3 (hu)
DE (1) DE60000842T2 (hu)
DK (1) DK1053746T3 (hu)
EA (1) EA004943B1 (hu)
ES (1) ES2185544T3 (hu)
FR (1) FR2793684B1 (hu)
HK (1) HK1047044B (hu)
HU (1) HUP0201224A3 (hu)
IL (2) IL146467A0 (hu)
MX (1) MXPA01011919A (hu)
NO (1) NO331686B1 (hu)
NZ (1) NZ515515A (hu)
PL (1) PL201614B1 (hu)
PT (1) PT1053746E (hu)
SI (1) SI1053746T1 (hu)
SK (1) SK16342001A3 (hu)
TW (1) TWI229608B (hu)
WO (1) WO2000069413A1 (hu)
ZA (1) ZA200109415B (hu)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE342084T1 (de) 1999-08-05 2006-11-15 Map Medizin Technologie Gmbh Vorrichtung zur zufuhr eines atemgases und befeuchtungsvorrichtung
AUPR098300A0 (en) 2000-10-25 2000-11-16 Sirtex Medical Limited Polymer based radionuclide containing microspheres
JP2002154963A (ja) * 2000-11-14 2002-05-28 Yakult Honsha Co Ltd 徐放性抗腫瘍剤
US20020081339A1 (en) * 2000-12-22 2002-06-27 Philippe Menei Treatment of inoperable tumors by stereotactic injection of microspheres
JP4510383B2 (ja) 2001-05-23 2010-07-21 田辺三菱製薬株式会社 軟骨疾患修復治療用組成物
KR20040007596A (ko) 2001-05-23 2004-01-24 다나베 세이야꾸 가부시키가이샤 골절 치료 촉진용 조성물
EP1411861B1 (en) 2001-06-29 2012-04-04 Medgraft Microtech, Inc. Biodegradable injectable implants and related methods of manufacture and use
UA77999C2 (en) * 2001-12-10 2007-02-15 Thymosin-alpha 1 for treatment of malignant glioblastoma
EP2075256A2 (en) 2002-01-14 2009-07-01 William Herman Multispecific binding molecules
US8986737B2 (en) 2002-09-05 2015-03-24 Wm. Marsh Rice University Antibiotic microspheres for treatment and prevention of osteomyelitis and enhancement of bone regrowth
NZ748073A (en) 2003-06-20 2020-06-26 ResMed Pty Ltd Breathable gas apparatus with humidifier
US20070026005A1 (en) * 2003-09-09 2007-02-01 Sung Young C Vaccine composition comprising il-12 adjuvant encapsulated in controlled-release microsphere
WO2005089398A2 (en) * 2004-03-18 2005-09-29 St. Luke's Hospital Method for the delivery of sustained release agents
US7833187B2 (en) 2004-04-16 2010-11-16 Nuvue Therapeutics, Inc. Systems and methods for improving image-guided tissue ablation
US8088413B2 (en) * 2004-04-16 2012-01-03 Nuvue Therapeutics, Inc. Methods for improved cryo-chemotherapy tissue ablation
CA2579533C (en) 2004-09-07 2013-05-21 Biocompatibles Uk Limited Drug delivery from embolic agents
US8702580B2 (en) * 2004-10-06 2014-04-22 Brainlab Ag Method and device for assisting in a tissue treatment
CN100386115C (zh) * 2004-10-14 2008-05-07 孔庆忠 一种抗癌药物组合物
CN1299685C (zh) * 2005-01-26 2007-02-14 上海大学 氟尿嘧啶载药微球及其制备方法
CN100340297C (zh) * 2005-02-03 2007-10-03 山东蓝金生物工程有限公司 抗癌体内植入剂
CN1923281B (zh) * 2005-08-30 2010-05-05 孔庆忠 一种含植物生物碱的抗癌缓释注射剂
CN100464785C (zh) * 2005-08-30 2009-03-04 孔庆忠 一种抗癌药物缓释注射剂及其应用
CN1923282B (zh) * 2005-08-30 2010-05-05 孔庆忠 一种含激素类药物的抗癌缓释注射剂
CN1923173B (zh) * 2006-02-24 2010-05-19 济南康泉医药科技有限公司 一种同载抗癌抗生素及其增效剂的抗癌药物缓释剂
WO2007105218A2 (en) * 2006-03-14 2007-09-20 Yeda Research And Development Co. Ltd. Composition and method for brain tumor therapy
CN100464736C (zh) * 2006-03-17 2009-03-04 山东蓝金生物工程有限公司 同载抗代谢药物及其增效剂的抗癌缓释注射剂
EP1985286A1 (en) * 2007-04-24 2008-10-29 Biocompatibles UK Limited Microspheres for treatment of brain tumours
SG10201601349XA (en) 2011-12-13 2016-03-30 Engeneic Molecular Delivery Pty Ltd Bacterially derived, intact minicells for delivery of therapeutic agents to brain tumors
US10342769B2 (en) * 2014-11-14 2019-07-09 Navinta Iii Inc Carmustine pharmaceutical composition
US20170128424A1 (en) * 2015-11-11 2017-05-11 Qrono, Inc. Sustained release pharmaceutical compositions and methods of use
AR112480A1 (es) 2017-08-24 2019-10-30 Novo Nordisk As Composiciones de glp-1 y sus usos
US20230093542A1 (en) 2020-02-18 2023-03-23 Novo Nordisk A/S Glp-1 compositions and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2693905B1 (fr) * 1992-07-27 1994-09-02 Rhone Merieux Procédé de préparation de microsphères pour la libération prolongée de l'hormone LHRH et ses analogues, microsphères et formulations obtenues.
NZ260909A (en) * 1993-07-05 1995-04-27 Takeda Chemical Industries Ltd Production of sustained release preparation by allowing a water-soluble polypeptide to permeate into a biodegradable matrix in an aqueous solution
US5626862A (en) * 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
CA2269075A1 (en) * 1996-10-16 1998-04-23 Regeneron Pharmaceuticals, Inc. Method of enhancing the delivery of growth factors
WO1998043977A1 (fr) * 1997-03-31 1998-10-08 Toray Industries, Inc. Derives de quinolinomorphinane et leur usage medical
AU745324B2 (en) * 1997-10-14 2002-03-21 Cenes Pharmaceuticals, Inc. Therapeutic methods comprising use of a neuregulin

Also Published As

Publication number Publication date
US7041241B2 (en) 2006-05-09
EA200101206A1 (ru) 2002-04-25
BG106106A (en) 2002-05-31
WO2000069413A1 (fr) 2000-11-23
AR024008A1 (es) 2002-09-04
JP2002544219A (ja) 2002-12-24
JP5230045B2 (ja) 2013-07-10
CN1210020C (zh) 2005-07-13
BR0010648A (pt) 2002-02-19
EP1053746A1 (fr) 2000-11-22
ATE228353T1 (de) 2002-12-15
US20020051749A1 (en) 2002-05-02
AU4764100A (en) 2000-12-05
DE60000842D1 (de) 2003-01-09
BG64936B1 (bg) 2006-10-31
IL146467A0 (en) 2002-07-25
US20030175356A1 (en) 2003-09-18
ES2185544T3 (es) 2003-05-01
MXPA01011919A (es) 2002-05-06
HK1047044A1 (en) 2003-02-07
TWI229608B (en) 2005-03-21
FR2793684A1 (fr) 2000-11-24
NO20015501D0 (no) 2001-11-09
PL352372A1 (en) 2003-08-25
KR20020000178A (ko) 2002-01-04
EA004943B1 (ru) 2004-10-28
CN1356892A (zh) 2002-07-03
HUP0201224A3 (en) 2004-05-28
CA2388656C (fr) 2011-04-26
NZ515515A (en) 2004-02-27
DE60000842T2 (de) 2003-08-28
SK16342001A3 (sk) 2002-08-06
NO331686B1 (no) 2012-02-20
IL146467A (en) 2006-06-11
PT1053746E (pt) 2003-04-30
CA2388656A1 (fr) 2000-11-23
DK1053746T3 (da) 2003-03-31
EP1053746B1 (fr) 2002-11-27
SI1053746T1 (en) 2003-04-30
NO20015501L (no) 2002-01-09
PL201614B1 (pl) 2009-04-30
ZA200109415B (en) 2003-01-29
HK1047044B (zh) 2005-12-23
AU775320B2 (en) 2004-07-29
CZ20014137A3 (cs) 2002-06-12
FR2793684B1 (fr) 2001-08-10
US6803052B2 (en) 2004-10-12
KR100649948B1 (ko) 2006-11-24
EP1228755A1 (fr) 2002-08-07

Similar Documents

Publication Publication Date Title
HUP0201224A2 (hu) Glioblasztóma kezelésére alkalmas rákellenes szert tartalmazó biodegradálható mikrogömbök alkalmazása gyógyszer termék előállítására
US6652884B2 (en) Method for the treatment of solid tumors by albumin microparticles incorporating paclitaxel
US6890950B2 (en) Lapachone delivery systems, compositions and uses related thereto
EP0290891B1 (en) Controlled drug delivery system for treatment of neural disorders
DE69529054D1 (de) System zur gezielten wirkstoffzufuhr, verfahren zu seiner herstellung und verwendung
ES2727273T3 (es) Terapias inhibidoras de la autofagia basadas en tioxantina para tratar el cáncer
US5871771A (en) Micronized biodegradable particles, process for preparing them and use thereof
JP2017528527A (ja) 治療薬の超局在化された放出のための注射可能な微粒子
CN109125739A (zh) 多功能高分子胶束药物递送系统及其制备方法和应用
ES469878A1 (es) Un procedimiento para preparar una composicion farmaceutica para el tratamiento del habito de consumir drogas
Zhong et al. New Progress in Improving the Delivery Methods of Bisphosphonates in the Treatment of Bone Tumors
US20120035531A1 (en) On-demand and reversible drug release by external cue
US5637085A (en) Method of cancer tumor treatment by slow release delivery of 1,2,4-benzotriazine oxides to tumor site
EP3275447B1 (en) Gel local anesthetic agent and gel local anesthetic preparation using same
CN108992418A (zh) 药物组合物、制备方法及其用途
CN1846672A (zh) 一种含抗代谢类药物的抗癌药物组合物
US11541061B2 (en) Neuroblastoma treatment with taurolidine hydrolysis products
CN101879143B (zh) 一种含有抗帕金森病药物的微球组合药物及其应用
McRae et al. Catecholamine-containing biodegradable microsphere implants as a novel approach in the treatment of CNS neurodegenerative disease: A review of experimental studies in DA-lesioned rats
Karale et al. Pros and cons of pulsatile drug delivery system
CN101879153B (zh) 一种左旋多巴甲酯和苄丝肼混和药物缓释微球组合物及其制备方法
Yakubova et al. S9. 710. Synthesis and application of calcium carbonate nanopar-ticles for combined therapy of oncological diseases
Hincal et al. Biomedical Science and Technology: Recent Developments in the Pharmaceutical and Medical Sciences
US8835453B2 (en) Sustained release implant for granisetron
Coderre et al. Boron neutron capture therapy of ocular melanoma and intracranial glioma using p-boronophenylalanine

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees